The BROX Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population generated from the HT29 human colorectal adenocarcinoma cell line, featuring targeted disruption of the BROX gene. The polyclonal nature of this product avoids clonal selection artifacts and provides a heterogeneous loss-of-function model that better reflects biological variability. These cells are designed as an advanced research tool for investigating the roles of BROX in ESCRT-mediated membrane trafficking and autophagy within a colorectal cancer context.
The HT29 cell line is a well-characterized human colorectal adenocarcinoma model established from a female patient. These cells exhibit an epithelial morphology and are capable of mucin production, reflecting their adenocarcinoma origin. Notably, HT29 cells are tumorigenic in vivo, making them a valuable system for studying colorectal cancer pathogenesis. They are widely utilized in oncology research for investigating signaling pathways, proliferation, metastasis, and drug resistance mechanisms. Additionally, HT29 cells are amenable to autophagy studies due to their metabolic adaptability, which is particularly relevant for examining the role of BROX in ESCRT-mediated processes.
BROX is an ESCRT-III-associated BRO1 domain protein that binds CHMP4B to facilitate membrane fission in cytokinetic abscission and autophagy. It also directly interacts with ATG8 family members LC3A/B and GABARAP via a LIR motif, bridging ESCRT complexes and the autophagy machinery. Upstream, BROX is activated by CHMP4B and ESCRT-III assembly, with inputs from mitotic signaling and starvation cues. Downstream, BROX drives abscission, autophagic flux, and endosomal cargo sorting. Together with VPS4, ALIX, and ubiquitinated substrates, BROX modulates autophagy effectors including p62, ATG7, and Beclin-1, regulating LC3 lipidation and autophagic degradation.
Disruption of BROX in HT29 colorectal cancer cells enables dissection of ESCRT-mediated processes in tumor biology. Loss of BROX is predicted to impair autophagic flux and cytokinetic abscission, affecting proliferation, migration, and drug resistance??key aspects of colorectal cancer. The mucinous, tumorigenic HT29 background provides a relevant model to study how BROX-dependent membrane trafficking contributes to cancer progression. This knockout system is valuable for examining ESCRT?Cautophagy crosstalk in an epithelial adenocarcinoma context.
The BROX Knockout HT29 Polyclonal Cells support a broad range of functional studies, including Western blotting for BROX, LC3-II, and p62, RT-qPCR for BROX mRNA, and immunofluorescence for CHMP4B or LC3. Proliferation, colony formation, cell cycle, and migration/invasion assays can assess the role of BROX in tumorigenic behavior. Autophagic flux is readily measured using bafilomycin A1 treatment, and abscission assays allow direct observation of cytokinetic defects. This model is therefore ideal for investigating ESCRT function, autophagy, cytokinesis, and drug resistance in a colorectal cancer context. For additional product information and technical support, please contact Ascent Research.
